Ilia I. Ouspenski

Array ( [id] => 12881479 [patent_doc_number] => 20180185668 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-05 [patent_title] => HUMAN ANTIBODIES TO PD-1 [patent_app_type] => utility [patent_app_number] => 15/905685 [patent_app_country] => US [patent_app_date] => 2018-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38013 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15905685 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15324141 [patent_doc_number] => 20200002400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-02 [patent_title] => CONSTRUCTION OF CHIMERIC ANTIGEN RECEPTOR TARGETING CD20 ANTIGEN AND ACTIVITY IDENTIFICATION OF ENGINEERED T CELLS THEREOF [patent_app_type] => utility [patent_app_number] => 16/484482 [patent_app_country] => US [patent_app_date] => 2018-02-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11307 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16484482 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13207139 [patent_doc_number] => 10117920 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-11-06 [patent_title] => Combination of vaccination and inhibition of the PD-1 pathway [patent_app_type] => utility [patent_app_number] => 15/890413 [patent_app_country] => US [patent_app_date] => 2018-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 3 [patent_figures_cnt] => 3 [patent_no_of_words] => 34141 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15890413 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12832090 [patent_doc_number] => 20180169202 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-21 [patent_title] => COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY [patent_app_type] => utility [patent_app_number] => 15/890736 [patent_app_country] => US [patent_app_date] => 2018-02-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34163 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15890736 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15264847 [patent_doc_number] => 20190381157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-12-19 [patent_title] => METHODS OF IMMUNE MODULATION AGAINST FOREIGN AND/OR AUTO ANTIGENS [patent_app_type] => utility [patent_app_number] => 16/479902 [patent_app_country] => US [patent_app_date] => 2018-01-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -67 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16479902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17713514 [patent_doc_number] => 11377497 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-07-05 [patent_title] => PD-L1 binding polypeptide or composite [patent_app_type] => utility [patent_app_number] => 16/479858 [patent_app_country] => US [patent_app_date] => 2018-01-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 42412 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16479858 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16642129 [patent_doc_number] => 10919965 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-02-16 [patent_title] => Compositions monovalent for CD28 binding and methods of use [patent_app_type] => utility [patent_app_number] => 15/870121 [patent_app_country] => US [patent_app_date] => 2018-01-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 14 [patent_no_of_words] => 55930 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 62 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15870121 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18504653 [patent_doc_number] => 11702458 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-07-18 [patent_title] => PD1-41BBL fusion protein and methods of use thereof [patent_app_type] => utility [patent_app_number] => 16/475705 [patent_app_country] => US [patent_app_date] => 2018-01-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 26 [patent_no_of_words] => 28797 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16475705 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12790777 [patent_doc_number] => 20180155428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-07 [patent_title] => BTLA Antibodies and Uses Thereof [patent_app_type] => utility [patent_app_number] => 15/860983 [patent_app_country] => US [patent_app_date] => 2018-01-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11582 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15860983 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060146 [patent_doc_number] => 11104733 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => PD-1 immune modulating agents [patent_app_type] => utility [patent_app_number] => 15/849107 [patent_app_country] => US [patent_app_date] => 2017-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 43 [patent_no_of_words] => 11862 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060146 [patent_doc_number] => 11104733 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => PD-1 immune modulating agents [patent_app_type] => utility [patent_app_number] => 15/849107 [patent_app_country] => US [patent_app_date] => 2017-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 43 [patent_no_of_words] => 11862 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060146 [patent_doc_number] => 11104733 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => PD-1 immune modulating agents [patent_app_type] => utility [patent_app_number] => 15/849107 [patent_app_country] => US [patent_app_date] => 2017-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 43 [patent_no_of_words] => 11862 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17060146 [patent_doc_number] => 11104733 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-08-31 [patent_title] => PD-1 immune modulating agents [patent_app_type] => utility [patent_app_number] => 15/849107 [patent_app_country] => US [patent_app_date] => 2017-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 43 [patent_no_of_words] => 11862 [patent_no_of_claims] => 36 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 176 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15849107 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13328577 [patent_doc_number] => 20180215826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-02 [patent_title] => VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCER [patent_app_type] => utility [patent_app_number] => 15/847132 [patent_app_country] => US [patent_app_date] => 2017-12-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 101411 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15847132 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15227619 [patent_doc_number] => 10501520 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-12-10 [patent_title] => B7-H5, a costimulatory polypeptide [patent_app_type] => utility [patent_app_number] => 15/845158 [patent_app_country] => US [patent_app_date] => 2017-12-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 11 [patent_no_of_words] => 10835 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 81 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15845158 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16785020 [patent_doc_number] => 10987419 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-27 [patent_title] => Immunostimulatory compositions, particles, and uses related thereto [patent_app_type] => utility [patent_app_number] => 15/833769 [patent_app_country] => US [patent_app_date] => 2017-12-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 12 [patent_no_of_words] => 11073 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 80 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15833769 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12660493 [patent_doc_number] => 20180111997 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-04-26 [patent_title] => Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Alzheimer's Disease [patent_app_type] => utility [patent_app_number] => 15/821595 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 160 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15821595 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12448590 [patent_doc_number] => 09982049 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Reducing systemic regulatory T cell levels or activity for treatment of alzheimer's disease [patent_app_type] => utility [patent_app_number] => 15/821603 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 56 [patent_no_of_words] => 19261 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15821603 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12680980 [patent_doc_number] => 20180118826 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-03 [patent_title] => Reducing Systemic Regulatory T Cell Levels or Activity for Treatment of Alzheimer's Disease [patent_app_type] => utility [patent_app_number] => 15/821570 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19269 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 131 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15821570 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12448596 [patent_doc_number] => 09982051 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-05-29 [patent_title] => Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS [patent_app_type] => utility [patent_app_number] => 15/821678 [patent_app_country] => US [patent_app_date] => 2017-11-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 20 [patent_figures_cnt] => 56 [patent_no_of_words] => 20900 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15821678 [rel_patent_id] =>[rel_patent_doc_number] =>)